Discussion on Expanding R&D Investment and Introducing the Quasi-Innovative System
Revising the Certification Standards for Innovative Pharmaceutical Companies

The government has launched a public-private consultative body to enhance the competitiveness of the pharmaceutical industry and foster domestic companies into global-level pharmaceutical firms. It will revamp the innovative pharmaceutical company certification system and newly introduce a "quasi-innovative pharmaceutical company" system targeting small and venture pharmaceutical companies that invest in research and development (R&D).


Pharmaceutical Industry Public-Private Consultative Body Launched... Stepwise Promotion from "Innovative" to "Global" View original image

The Ministry of Health and Welfare announced on September 2 that it had formed the "1st Pharmaceutical Industry Innovation Public-Private Consultative Body" and held its first meeting at Koreana Hotel in Jung-gu, Seoul, with participation from related ministries, the pharmaceutical and biotech industries, experts, and public institutions.


The consultative body is co-chaired by Lee Hyunghoon, the Second Vice Minister of Health and Welfare, and No Yeonhong, Chairman of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association. It consists of 21 members, including government and public institution officials, related associations, pharmaceutical and biotech industry stakeholders, and industrial experts. The group will focus on discussions regarding: ▲Fostering both innovative and quasi-innovative pharmaceutical companies, ▲Strengthening management and oversight of contract sales organizations (CSOs), ▲Promoting the scaling-up, specialization, and export capabilities of generic-centric companies, ▲Encouraging the development of biologic drugs, improved drugs, and natural substance new drugs, and ▲Driving innovation in new drug development and manufacturing using artificial intelligence (AI).


At the meeting, particular attention was given to improving the innovative pharmaceutical company certification system and plans for new certifications. Previously, in July, the Ministry amended the enforcement ordinances, rules, and notifications to adjust certification standards.


Firstly, the R&D investment requirements for innovative pharmaceutical companies were raised. For companies with annual pharmaceutical sales of less than 100 billion won, the R&D investment ratio to sales increased from the previous 7% to 9%, and the minimum R&D investment amount was raised from 5 billion won to 7 billion won. For companies with sales of 100 billion won or more, the requirement was raised from 5% to 7%, and for those meeting U.S. and European GMP standards, from 3% to 5%, respectively.


The certification evaluation method was streamlined: the previous total of 120 points across 25 detailed review items has been simplified to a 100-point scale across 17 items, with major indicators such as R&D investment, the number of clinical trials at each stage, and export scale being quantified. The weighting for partnership and collaboration activities, non-clinical and clinical trials, overseas market entry, and social responsibility was increased, whereas the weighting for research personnel, research and production facilities, and R&D strategy was lowered for some items.


Regarding rebates, violations that occurred more than 5 years prior to the certification review date are no longer grounds for disqualification. However, if administrative dispositions under the Pharmaceutical Affairs Act or the Fair Trade Act are challenged in court, certification can be revoked within 1 year after the verdict is finalized.


A separate certification category will be established for foreign pharmaceutical companies. Applicants can choose between domestic and foreign criteria, and related scoring will be adjusted to promote the construction of domestic research and production facilities and open innovation. In addition, a minimum passing score of 65 points will be specified, and companies that fail will be individually notified of their non-certification status and the reasons for rejection.


The application period for new innovative pharmaceutical company certifications in the second half of the year is open until the 18th, and following review, the final selection and notification will be made at the December meeting of the Pharmaceutical Industry Promotion and Support Committee.


The quasi-innovative pharmaceutical company system is also being newly introduced. The Ministry of Health and Welfare plans to support promising small and venture pharmaceutical companies that invest a certain level in R&D, thereby creating a stepwise growth structure of "startup → quasi-innovative pharmaceutical company → innovative pharmaceutical company → global-level pharmaceutical company." Quasi-innovative companies will be granted benefits such as preferential pricing for generic drugs.



Lee Hyunghoon, the Second Vice Minister of Health and Welfare, stated, "Through this consultative body, we hope to share the current status of Korea's pharmaceutical industry and establish pathways for nurturing and developing the industry that will drive Korea's future growth, through in-depth discussions."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing